{"id":"W2592578668","doi":"10.1200/jco.2009.27.15_suppl.e12019","title":"An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Pfizer (Canada); Montreal General Hospital","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Sunitinib; Exemestane; Bevacizumab; Letrozole; Regimen; Oncology; Palbociclib; Pharmacology; Progression-free survival; Breast cancer; Aromatase inhibitor; Pharmacokinetics; Gastroenterology; Cancer; Tamoxifen; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001432801,0.001620267,0.002978445,0.0007180547,0.0006169927,0.001199049,0.00124906,0.001757345,0.005658036],"category_scores_gemma":[0.001187896,0.0008636527,0.001557984,0.0004700025,0.001211117,0.001802249,0.0004359436,0.003374258,0.00116558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001158188,"about_ca_system_score_gemma":0.001618486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001247663,"about_ca_topic_score_gemma":0.003662635,"domain_scores_codex":[0.999472,0.0002338278,0.00003285721,0.0000988855,0.00004773184,0.0001146403],"domain_scores_gemma":[0.9989656,0.0002120596,0.0001559506,0.00008187439,0.00006082038,0.0005235637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8195738,0.1223104,0.001683127,0.0006030761,0.0005696134,0.0001603072,0.0002036166,0.001037877,0.01457193,0.0001334006,0.0009621518,0.03819088],"study_design_scores_gemma":[0.4073522,0.5853322,0.003631347,0.00002101317,0.0002204276,0.0001159783,0.00005279428,0.0006936851,0.00145801,0.00009335845,0.001005314,0.00002370153],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941772,0.001069006,0.0003003707,0.0001757199,0.000173482,0.002238263,0.0006266194,0.00007121391,0.001168041],"genre_scores_gemma":[0.9919556,0.001229816,0.001081255,0.0003893263,0.0002609599,0.001700177,0.0009079689,0.0000216748,0.002453127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005658036,"threshold_uncertainty_score":0.01892799,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08892945395639623,"score_gpt":0.459016489290721,"score_spread":0.3700870353343247,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}